MX2022011635A - Radioinmunoconjugados dirigidos a fgfr3 y usos de estos. - Google Patents
Radioinmunoconjugados dirigidos a fgfr3 y usos de estos.Info
- Publication number
- MX2022011635A MX2022011635A MX2022011635A MX2022011635A MX2022011635A MX 2022011635 A MX2022011635 A MX 2022011635A MX 2022011635 A MX2022011635 A MX 2022011635A MX 2022011635 A MX2022011635 A MX 2022011635A MX 2022011635 A MX2022011635 A MX 2022011635A
- Authority
- MX
- Mexico
- Prior art keywords
- radioimmunoconjugates
- fgfr3
- targeted
- pharmaceutical compositions
- linker
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1054—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/106—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from kidney or bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062993622P | 2020-03-23 | 2020-03-23 | |
| PCT/US2021/023755 WO2021195131A1 (en) | 2020-03-23 | 2021-03-23 | Fgfr3-targeted radioimmunoconjugates and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011635A true MX2022011635A (es) | 2022-10-13 |
Family
ID=77892654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011635A MX2022011635A (es) | 2020-03-23 | 2021-03-23 | Radioinmunoconjugados dirigidos a fgfr3 y usos de estos. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230201384A1 (enExample) |
| EP (1) | EP4126074A4 (enExample) |
| JP (1) | JP2023518818A (enExample) |
| KR (1) | KR20220157464A (enExample) |
| CN (1) | CN115315274A (enExample) |
| AR (1) | AR121643A1 (enExample) |
| AU (1) | AU2021244464A1 (enExample) |
| BR (1) | BR112022019226A2 (enExample) |
| CA (1) | CA3176617A1 (enExample) |
| CL (1) | CL2022002557A1 (enExample) |
| IL (1) | IL295999A (enExample) |
| MX (1) | MX2022011635A (enExample) |
| TW (1) | TW202144008A (enExample) |
| WO (1) | WO2021195131A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025500944A (ja) * | 2021-12-20 | 2025-01-15 | フュージョン・ファーマシューティカル・インコーポレイテッド | ＥＧＦＲ－ｃＭＥＴ標的化合物及びその使用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015001724A2 (pt) * | 2012-07-27 | 2018-04-03 | Genentech Inc | métodos de tratamento de condições relacionadas a fgfr3 |
| CA2961439A1 (en) * | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
| SG11201706727XA (en) * | 2015-02-19 | 2017-09-28 | Bioclin Therapeutics Inc | Methods, compositions, and kits for treatment of cancer |
| CN110785184A (zh) * | 2017-02-06 | 2020-02-11 | 雷尼尔医疗公司 | 用于治疗癌症的方法，组合物和试剂盒 |
| WO2018204872A2 (en) * | 2017-05-05 | 2018-11-08 | Fusion Pharmaceuticals Inc. | Igf-1r monoclonal antibodies and uses thereof |
| AU2018261888B2 (en) * | 2017-05-05 | 2022-06-30 | Centre For Probe Development And Commercialization | Pharmacokinetic enhancements of bifunctional chelates and uses thereof |
| KR20250047324A (ko) * | 2017-08-07 | 2025-04-03 | 더 존스 홉킨스 유니버시티 | 암을 평가하고 치료하기 위한 방법 및 재료 |
| TW202131946A (zh) * | 2020-01-10 | 2021-09-01 | 加拿大商融合製藥公司 | 持續性免疫療法 |
-
2021
- 2021-03-23 KR KR1020227036615A patent/KR20220157464A/ko not_active Ceased
- 2021-03-23 CA CA3176617A patent/CA3176617A1/en active Pending
- 2021-03-23 AR ARP210100720A patent/AR121643A1/es not_active Application Discontinuation
- 2021-03-23 AU AU2021244464A patent/AU2021244464A1/en not_active Abandoned
- 2021-03-23 BR BR112022019226A patent/BR112022019226A2/pt not_active IP Right Cessation
- 2021-03-23 EP EP21775240.1A patent/EP4126074A4/en not_active Withdrawn
- 2021-03-23 IL IL295999A patent/IL295999A/en unknown
- 2021-03-23 JP JP2022557117A patent/JP2023518818A/ja active Pending
- 2021-03-23 MX MX2022011635A patent/MX2022011635A/es unknown
- 2021-03-23 TW TW110110479A patent/TW202144008A/zh unknown
- 2021-03-23 CN CN202180023427.1A patent/CN115315274A/zh active Pending
- 2021-03-23 WO PCT/US2021/023755 patent/WO2021195131A1/en not_active Ceased
- 2021-03-23 US US17/906,857 patent/US20230201384A1/en not_active Abandoned
-
2022
- 2022-09-21 CL CL2022002557A patent/CL2022002557A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021244464A1 (en) | 2022-11-24 |
| CN115315274A (zh) | 2022-11-08 |
| KR20220157464A (ko) | 2022-11-29 |
| IL295999A (en) | 2022-10-01 |
| JP2023518818A (ja) | 2023-05-08 |
| AR121643A1 (es) | 2022-06-22 |
| CL2022002557A1 (es) | 2023-05-19 |
| US20230201384A1 (en) | 2023-06-29 |
| EP4126074A1 (en) | 2023-02-08 |
| EP4126074A4 (en) | 2024-11-20 |
| BR112022019226A2 (pt) | 2022-11-08 |
| WO2021195131A1 (en) | 2021-09-30 |
| TW202144008A (zh) | 2021-12-01 |
| CA3176617A1 (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20267886B (en) | Exatecan derivatives and antibody-drug conjugates thereof | |
| MX2024000612A (es) | Inmunoconjugados y metodos. | |
| PH12020500396A1 (en) | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof | |
| BR112023002417A2 (pt) | Conjugado de anticorpo e fármaco | |
| MX2024007596A (es) | Compuestos dirigidos a egfr-cmet y usos de estos. | |
| PH12020550898A1 (en) | Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide | |
| NZ775660A (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| MX2022008605A (es) | Quelatos macrociclicos y sus usos. | |
| SA523442921B1 (ar) | جزيئات ربط علاجية | |
| MX2022003740A (es) | Inmunoconjugados de aminobenzazepina unidos a amida y usos de estos. | |
| EA201992595A1 (ru) | Усиление фармакокинетики бифункциональных хелатов и их применения | |
| ZA201907225B (en) | Treatment of her2 positive cancers | |
| MX2025000552A (es) | Conjugados anticuerpo-fármaco | |
| MY209745A (en) | Anti-mesothelin eribulin antibody-drug conjugates and methods of use | |
| MX2025005811A (es) | Conjugados de anticuerpo ceacam5-fármaco y métodos de uso de los mismos | |
| MX2019011506A (es) | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. | |
| ZA202302155B (en) | Interferon-based cancer treatment method and pharmaceutical composition | |
| MX2021011703A (es) | Composiciones y métodos para alterar el fenotipo de macrófagos. | |
| ZA202101990B (en) | Sulfomaleimide-based linkers and corresponding conjugates | |
| MX2025004144A (es) | Anticuerpo anti-gucy2c y usos del mismo | |
| MX2025015010A (es) | Peptidos dirigidos a dll3 y sus construcciones | |
| MX2025006740A (es) | Composiciones farmacéuticas que contienen una de piperidinil-metil-purina amina y su uso en el tratamiento de enfermedades y afecciones | |
| SG11201910113PA (en) | Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate | |
| MY200161A (en) | Bacteria for targeting tumors and treating cancer | |
| MX2025015006A (es) | Peptidos dirigidos a dll3 y constructos de estos |